1813-93-0

Basic information

• Product Name: ETHYL 2-FLUOROBENZOYLFORMATE
• Synonyms: ETHYL 2-FLUOROBENZOYLFORMATE;ethyl 2-(2-fluorophenyl)-2-oxoacetate;2-Fluoro-oxo-benzeneacetic acid ethyl ester
• CAS NO: 1813-93-0
• Molecular Formula: C₁₀H₉FO₃
• Molecular Weight: 196.18
• Mol File: 1813-93-0.mol

Chemical Properties

• Boiling Point: 271.2°C at 760 mmHg
• Flash Point: 114.3°C
• Appearance: /
• Density: 1.213g/cm³
• Vapor Pressure: 0.00654mmHg at 25°C
• Refractive Index: 1.497
• Storage Temp.: Sealed in dry,Room Temperature
• CAS DataBase Reference: ETHYL 2-FLUOROBENZOYLFORMATE(CAS DataBase Reference)
• NIST Chemistry Reference: ETHYL 2-FLUOROBENZOYLFORMATE(1813-93-0)
• EPA Substance Registry System: ETHYL 2-FLUOROBENZOYLFORMATE(1813-93-0)

Safety Data

• HazardClass: IRRITANT
• Hazardous Substances Data: 1813-93-0(Hazardous Substances Data)

Usage

Uses

Used in Chemical Research and Development:
ETHYL 2-FLUOROBENZOYLFORMATE is used as a research chemical for the synthesis and formulation of different chemical products. Its unique properties make it a valuable compound in the development of new materials and processes.
Used in Industrial Applications:
In the industrial sector, ETHYL 2-FLUOROBENZOYLFORMATE is used as a key component in the production of various chemical products. Its versatility and reactivity contribute to the creation of new compounds and materials that serve various purposes in different industries.

InChI:InChI=1/C10H9FO3/c1-2-14-10(13)9(12)7-5-3-4-6-8(7)11/h3-6H,2H2,1H3

Upstream product

• 348-52-7 1-Fluoro-2-iodobenzene 
• 4755-77-5 Ethyl oxalyl chloride 
• 1240912-19-9 ethyl 2-diazo-3-(2-fluorophenyl)-3-oxopropanoate 
• 1072-85-1 o-fluorobromobenzene 
• 95-92-1 oxalic acid diethyl ester 
• 446-52-6 2-Fluorobenzaldehyde 
• 64-17-5 ethanol 
• 389-31-1 2-fluoromandelic acid 
• 109-72-8 n-butyllithium 
• 75716-82-4 imidazol-1-yl-oxo-acetic acid ethyl ester 

Downstream Products

• 698378-76-6 ethyl α,α-difluoro-α-(o-fluorophenyl)acetate 
• 1380202-32-3 2,2-difluoro-2-(2-fluoro-phenyl)-ethanol 
• 1380202-34-5 1-(2-azido-1,1-difluoroethyl)-2-fluorobenzene 
• 1380202-36-7 2,2-difluoro-2-(2-fluorophenyl)-ethylamine 
• 1380201-88-6 2,2-difluoro-2-(2-fluorophenyl)-ethylsulfamide 
• 79477-86-4 2-fluorophenylglyoxylic acid 
• 586965-70-0 (S)-(+)-flutriafol 
• 1053246-13-1 (S)-2-(2-fluorophenyl)-2-(4-fluorophenyl)oxirane 
• 1053246-11-9 (S)-1-(2-fluorophenyl)-1-(4-fluorophenyl)ethane-1,2-diol 

Relevant articles and documents

Copper(I)-catalyzed aerobic oxidation of α-diazoesters

A practical Cu-catalyzed oxidation of α-diazoesters to α-ketoesters using molecular oxygen as an oxidant has been developed. Both electron-poor and electron-rich aryl α-diazoesters are suitable substrates and provide the α-ketoesters in good yields. In this oxidative system, α-diazo-β-ketoesters are also compatible as substrates but unexpectedly furnish α-ketoesters via C-C bond cleavage, rather than the vicinal tricarbonyl products.

Stereospecific Nucleophilic Substitution with Arylboronic Acids as Nucleophiles in the Presence of a CONH Group

Stereospecific nucleophilic substitution was achieved for the first time with arylboronic acids as nucleophiles. This transition-metal-free coupling between chiral α-aryl-α-mesylated acetamides and arylboronic acids provided access to a series of chiral α,α-diaryl acetamides with excellent enantioselectivity and moderate to good yields. The CONH functionality proved to be crucial for bridging the reactants and promoting the reaction. Efficient syntheses of a cannabinoid CB1 receptor ligand, the antidepressant (S)-diclofensine, and a key chiral building block of the inhibitor implitapide were successfully accomplished by using this method.

Discovery of novel 2-(3-phenylpiperazin-1-yl)-pyrimidin-4-ones as glycogen synthase kinase-3β inhibitors

We herein describe the results of further evolution of glycogen synthase kinase (GSK)-3β inhibitors from our promising compounds containing a 2-phenylmorpholine moiety. Transformation of the morpholine moiety into a piperazine moiety resulted in potent GSK-3β inhibitors. SAR studies focused on the phenyl moiety revealed that a 4-fluoro-2-methoxy group afforded potent inhibitory activity toward GSK-3β. Based on docking studies, new hydrogen bonding between the nitrogen atom of the piperazine moiety and the oxygen atom of the main chain of Gln185 has been indicated, which may contribute to increased activity compared with that of the corresponding phenylmorpholine analogues. Effect of the stereochemistry of the phenylpiperazine moiety is also discussed.

Cationic Ir/Me-BIPAM-catalyzed asymmetric intramolecular direct hydroarylation of α-ketoamides

Asymmetric intramolecular direct hydroarylation of α-ketoamides gives various types of optically active 3-substituted 3-hydroxy-2-oxindoles in high yields with complete regioselectivity and high enantioselectivities (84-98 % ee). This is realized by the use of the cationic iridium complex [Ir(cod) 2](BArF4) and the chiral O-linked bidentate phosphoramidite (R,R)-Me-BIPAM. Carbon's got a brand new bond: Asymmetric intramolecular direct hydroarylation of α-ketoamides gives various optically active 3-substituted 3-hydroxy-2-oxindoles in high yields with complete regioselectivity and high enantioselectivities. This is realized by the use of an asymmetric cationic iridium complex formed in situ (see Scheme).

NOVEL FLUORINATED SULFAMIDES EXHIBITING NEUROPROTECTIVE ACTION AND THEIR METHOD OF USE

Pharmaceutical compositions of the invention include fluorinated sulfamide derivatives having a disease-modifying action in the treatment of diseases associated with excitotoxicity and accompanying oxidative stress that include epilepsy, Alzheimer's disea

PYRROLIDINE-FUSED THIADIAZINE DIOXIDE COMPOUNDS AS BACE 1NHIBITORS, COMPOSITIONS, AND THEIR USE

In its many embodiments, the present invention provides provides certain iminothiadiazine dioxide compounds, including compounds Formula (I): and tautomers and stereoisomers thereof, and pharmaceutically acceptable salts of said compounds, said tautomeros and said stereoisomers, where in each of W, Z, R1H, R2, R3, R4, ring A, ring B, m, n, p, and- L1 - is as defined herein. The novel compounds of the invention have surprisingly been found to exhibit properties which are expected to render them advantageous as BACE inhibitors and/or for the treatment and prevention of various pathologies related there to. Pharmaceutical compositions comprising one or more such compounds (alone and in combination with one or more other active agents), and methods for their preparation and use, including Alzheimer?s disease, are also disclosed

6-Beta-(alpha-etherified oxymino)-acyl amino penicillins

Compounds of formula (I): wherein R1 is optionally substituted phenyl and R is a cycloalkyl group having an alkyl substituent in the 1-position; or R1 is phenyl substituted by at least one fluorine atom and/or at least one trifluoromethyl group and R is hydrogen or an organic radical, and their salts and esters, are useful in the treatment of bacterial infections in humans and animals.